After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on ...